Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: A pediatric oncology group study

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2494-2499

  Langevin, Anne Marie ^a   Casto, Daniel T ^a   Thomas, Paul J ^a   Weitman, Steven D ^a   Kretschmar, Cynthia ^a   Grier, Holcombe ^a   Pratt, Charles ^a   Dubowy, Ronald ^a   Bernstein, Mark ^a   Blaney, Susan ^a   Vietti, Teresa ^a  

^a c/o Pediatric Oncology Group ^*

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031803526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2494     Document Type: Article

References (18)

1. Pommier Y: Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecins. Semin Oncol 23:3-10, 1996 (suppl 3)
2. Slichenmeyer WR, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
3. Dahut W, Harold N, Takimoto C, et al: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244, 1996
4. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995
5. Pratt CB, Stewart CF, Santana VM, et al: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539-543, 1994
6. Tubergen DG, Stewart CF, Pratt CB, et al: Phase I trial and pharmacokinetics study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:352-361, 1996
7. Furman WL, Baker SD, Pratt CB, et al: Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14:1504-1511, 1996
8. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
9. Supko JG, Malspeis L: Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liquid Chromotog 15:3261-3283, 1992
10. Gibaldi M, Perrier D. Pharmacokinetics (ed 2). New York, NY, Dekker, 1982, pp 321-322
11. Perrier D, Mayersohn M: Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71:372-373, 1982
12. Takimoto CH, Dahut W, Marino MT, et al: Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15:1492-1501, 1997
13. Spicer ST, Liddle C, Chapman JR, et al: The mechanism of cyclosporin toxicity induced by clarithromycin. Br J Clin Pharmacol 43:194-196, 1997
14. Honig P, Wortham D, Zamani K, et al: Effects of erythromycin, clarithromycin and azithromycin on the pharmacokinetics of terfenadine. Clin Pharmacol Ther 53:161, 1993 (abstr)
15. Grossman SA, Hochberg F, Fisher J, et al: Increased 9-aminocamptothecin (9-AC) dose requirements in patients on anticonvulsants (AC). Proc Am Soc Clin Oncol 16:389a, 1997 (abstr 1387)
16. Gajjar AJ, Heideman RL, Houghton PJ, et al: Phenytoin increases topotecan clearance in a patient with medulloblastoma. Proc Am Soc Clin Oncol 16:251a, 1997 (abstr 889)
17. Giovanella BC, Wall ME, Wani MC, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
18. Reilly S, Rowinsky E, Slichenmeyer WR, et al: Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 88:817-823, 1996